Biotechnology London, UK-based cell therapy specialist Quell Therapeutics today announced the closing of an extended Series A financing led by its existing investors Syncona, which has committed an additional $34.7 million and UCL Technology Fund (UCLTF), which has committed an additional $1 million; bringing the total Series A financing to circa $84 million. 11 February 2021